| Revenue Growth YoY | 62%FY26 Consolidated |
|---|---|
| Net Profit (PAT) | ₹122 Cr108% YoY Growth |
| Market Cap | ₹4,396 CrPharmaceuticals |
| Day RSI | 66.67Strong Zone |
Key highlights
- Consolidated revenue for FY26 reached ₹664 crore, marking a 62% year-on-year increase
- Profit After Tax (PAT) surged by 108% to ₹122 crore, significantly outpacing revenue growth
- EBITDA margins expanded by 526 basis points to reach 30% for the full year
- The approved ANDA portfolio doubled from 22 in FY25 to 51 approved filings by the end of FY26
- US regulated market revenue registered a robust growth of 75% during the fiscal year
- Management issued guidance for FY27 targeting 30-40% revenue growth and 50-60% PAT growth
Financial Performance and Operational Efficiency
Senores Pharmaceuticals demonstrated significant operational leverage in FY26, as profit growth of 108% substantially outpaced the 62% rise in consolidated revenue. This performance was driven primarily by the company's expansion into the US regulated markets, which saw a 75% increase in revenue contribution. EBITDA margins reached 30% for the year, supported by a 32.7% margin in the fourth quarter.
The company has successfully pivoted from a CDMO-heavy model toward direct sales of its own approved products, allowing for better realization and pricing power, especially in niche molecule segments.
Expansion and Strategic Outlook
The company has issued a confident outlook for FY27, projecting revenue growth between 30% and 40% with a corresponding PAT growth of 50-60%. This optimism is backed by a robust product pipeline and recent infrastructure acquisitions. Senores doubled its approved ANDA portfolio to 51 during the year, with plans to launch an additional 30 products over the next few quarters.
The integration of Apna Pharma, a USFDA-approved facility, and the Zoraya distribution network in the US are expected to further solidify the company's commercial footprint in regulated geographies.
Segmental and Market Dynamics
- Regulated Markets: Revenue grew by 75%, supported by the doubling of the approved ANDA portfolio to 51 molecules
- Emerging Markets: Achieved 20% growth and reached cash-flow positive status with improved per-unit realizations
- India Business: Branded generic revenue stood at ₹40 crore, growing nearly five times compared to the previous year
- Capital Expenditure: Invested ₹230 crore in FY26, with an additional ₹200 crore planned for FY27 to expand injectable capacities
- Strategic Partnerships: Entered a joint venture, Amerisource, to access US federal government and military procurement contracts
What to Watch
- Execution and launch timelines for the 30 approved ANDAs covering 100+ product strengths
- Potential impact of global logistical costs and inflationary pressures on US operational margins
- Integration and capacity utilization levels at the newly acquired Apna Pharma manufacturing facility
- Revenue contribution from the US government procurement joint venture in the upcoming quarters
Management Perspective
We believe we will continue to outperform industry growth. In parallel, we have continued to diversify our product portfolio, geographic presence by strengthening our reach in emerging and domestic markets.
“For FY27, our initial outlook indicates a revenue growth of approximately 30 to 40% and our PAT growth of about 50 to 60%.”
“Our approved ANDA portfolio has more than doubled, increasing from 22 ANDAs in March 25 to 51 approved ANDAs in March 26, reflecting the scale and the pace of our execution.”
| Share price | ₹954.65 |
|---|---|
| Market capitalisation | ₹4,396.51 Cr |
| Revenue (annual) | ₹398.25 Cr |
| Net profit (annual) | ₹58.56 Cr |
| Revenue (latest quarter) | ₹175.19 Cr+0.36% vs previous quarter |
| Net profit (latest quarter) | ₹31.61 Cr-0.16% vs previous quarter |
| P/E (TTM) | 38.1×Sector 42.13× |
| Promoter holding | 45.82%+0.02% QoQ |
| FII holding | 3.64%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Senores Pharmaceuticals Limited announcing the consolidated audited financial results for the quarter and year ended March 31, 2026. Market figures from a third-party data provider.
